Universal HealthcareBy NextBestFit

Reduces income or business for affected groups

The approach reduces payments, earnings, or business for some participants. This matters most when they cannot readily adjust and less when the loss can be absorbed without disrupting needed services.

Under your mix of paths

Paths that create or worsen it
Using your saved plan. 0 paths picked.Edit all picks

Caused or worsened by these paths

A cost these paths share. Each path's page says how it applies there.

Cap commercial prices at a multiple of MedicareU.S. prices are far higher than in other countriesChosen

Hospitals reliant on high commercial payments lose revenue under the cap.

Site-neutral paymentFacility fees: the same service costs more in a hospital-owned buildingChosen

Hospitals lose revenue that partly supports emergency and standby capacity.

Publicly funded EMS as essential serviceGetting to care: transportation and ambulancesChosen

Budget-funded ambulances reduce business for private ambulance companies.

Raise primary care pay relative to specialtiesPhysician shortage, especially in primary careChosen

Shifting fee-schedule dollars from procedures to primary care reduces specialist income.

Capitation for primary care and integrated systemsU.S. prices are far higher than in other countriesChosen

Fixed payments per enrolled person leave small practices bearing financial risk.

Shift spending toward primary careWorse outcomes than peer countries despite the highest spendingChosen

A higher primary care spending share requires money to come from specialists or hospitals.

Equity-adjusted fundingRacial, income, and geographic disparitiesChosen

Deprivation-based payments leave providers in wealthier areas receiving less.

No-fault compensation for medical injuryMalpractice system: slow, costly, and drives defensive medicineChosen

Compensation through a fund instead of lawsuits leaves lawyers with fewer cases.

Accept somewhat slower adoptionSlower access to new drugs and technologyRejected

Negotiating lower prices and assessing new treatments reduces manufacturer revenue.